Leukemia and Lymphoma

Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.

Older patients with chronic lymphocytic leukemia (CLL) appear to be more likely to have severe symptoms if they contract coronavirus disease 2019, according to new research.

A new analysis of nearly 3 decades of data suggests leukemia rates are falling, except for 2 specific types.

FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.

Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy are new and important treatments revolutionizing care of some cancers; however, their side effects can be very different than what is seen in traditional approaches, such as chemotherapy.

Treating children with aggressive B-cell lymphoma with rituximab can improve cure rates to up to 95%.

Patients with B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia can benefit greatly from chimeric antigen receptor (CAR) T-cell therapy, but providing that therapy has become much more difficult in the age of coronavirus disease 2019 (COVID-19).

The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The oral treatment is to be used after at least 2 lines of systemic therapy.

Most studies of patients with diffuse large B-cell lymphoma do not include those over the age of 80. However, a new study says those patients, like younger patients, benefit from receiving rituximab and anthracycline in their chemotherapy regimens when possible.

Diagnosis pediatric acute lymphoblastic leukemia (ALL) can be a costly and cumbersome experience. New research has identified microRNA signatures that could simplify the process of diagnosis and classifying the cancer.

Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.

A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the authors find many questions remain unsolved.

Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty care center.

Peripheral T-cell lymphoma (PTCL) has been a challenging nemesis for scientists, in large part because it is a widely heterogeneous disease. However, new research into biomarkers for the cancer may lead to better therapies soon.

The bruton tyrosine kinase inhibitor zanubrutinib was shown to generate high response rates in a new study of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Five metabolic inhibitors appear to have strong antiproliferative effects on acute myeloid leukemia (AML), according to a new study.

Patients who are treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia are at a higher risk of a secondary malignancy. A new case study suggest the list of potential secondary malignancies should include lymphoplasmacytic lymphoma.

Nivolumab-based first-line treatment is highly effective in patients with early-stage unfavorable classic Hodgkin lymphoma, according to results from the Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma trial published in JAMA Oncology.

Chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) is rare, making it difficult to differentiate from other types of lymphoma. A new study helps explain key unique traits.

A new pooled analysis of rituximab/bendamustine and rituximab/cytarabine in transplant-eligible patients with mantle cell lymphoma (MCL) finds it leads to durable positive results in most patients.

Patients with lymphoma have better odds of survival now than they did 20 years ago, according to new research. The data also help explain which types of cancer continue to be the most challenging.

A new study based on treatment of patients with chronic lymphocytic leukemia (CLL) in mostly community settings challenges earlier findings about the superiority of a common therapeutic approach and also makes a strong case for ibrutinib.

Investigators trying to find a way to stop antigen loss following CD19 CAR T cell therapy found an approach simultaneously targeting CD19 and CD22 is safe and feasible.

A new study shows patients with a history of lymphoma benefit from early detection of lung cancer, and are often good candidates for resection surgery.

Age and severe comorbidities were among the differences found when real-world data on Medicare patients receiving CAR T-cell therapy was compared to clinical trial outcomes, said Karl Kilgore, PhD, senior research analyst at Avalere Health.

Ibrutinib has been successful at fighting chronic lymphocytic leukemia (CLL), but new research finds interruptions in treatment with the drug can have a negative impact on patient outcomes.

TG Therapeutics announced that their investigational dual inhibitor drug umbralisib was granted orphan drug designation by the FDA for treatment of patients with follicular lymphoma.

Several challenges arise when using real-world data derived from claims to study the impacts of CAR T-cell therapy on Medicare patients, said Karl Kilgore, PhD, senior research analyst at Avalere Health.

A new review article highlights the remaining challenge to making a meaningful immunotherapy to combat acute myeloid lymphoma (AML).

Patients with relapsing/remitting chronic lymphocytic leukemia (CLL) have a range of new therapeutic options. A new study is the first to directly compare 2 of the more prominent new therapies.